Rita Peters talks with Jeffery C. Basham, vice president, business development at Metrics about the pharmaceutical industry's challenges with solubility and bioavailability. The video was recorded live at the Interphex 2013 trade show. In this video they discuss the factors that have contributed to the rise in the number of poorly-water soluble compounds in development
Recorded live at the Interphex 2013 trade show, Rita Peters asks Jeffery C. Basham, vice president, business development: From your experience, do you find that the related project work for solubility/bioavailability enhancement is mostly applied for new drug development or do you see it also driving growth in projects for product lifecycle management, for example, to improve dosing schemes/regimes? Can you provide an example of either case?
Check out the rest of the interview:
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.